Louisiana legislation · 2026 Regular Session
Louisiana SB169: GENETICS: Provides relative to biomarker testing. (gov sig) (EN NO IMPACT See Note)
Status: Signed into law, May 29, 2026
What the bill says
An act To amend and reenact R.S. 22:1028.5(D) and to enact R.S. 22:1028.5(B)(4) and (F), relative to biomarker testing; to clarify what constitutes clinical utility; to prevent coverage from being nullified through lab classification; to provide for construction of laws; to provide for an effective date; and to provide for related matters.
From the introduced text:
AN ACT To amend and reenact R.S. 22:1028.5(D) and to enact R.S. 22:1028.5(B)(4) and (F), relative to biomarker testing; to clarify what constitutes clinical utility; to prevent coverage from being nullified through lab classification; to provide for construction of laws; to provide for an effective date; and to provide for related matters. Be it enacted by the Legislature of Louisiana: Section 1. R.S. 22:1028.5(D) is hereby amended and reenacted and R.S. 22:1028.5(B)(4) and (F) are hereby enacted to read as follows: §1028.5. Required coverage for biomarker testing * * * B.(1) * * * * * * (4) For purposes of this Section, clinical utility shall be deemed demonstrated when a biomarker test meets any one of the criteria listed in Paragraph (2) of this Subsection. * * * D.(1) A health coverage plan shall ensure that the coverage prescribed in Page 1 of Coding: Words which are struck through are deletions from existing law; words in boldface type and underscored are additions. SLS 26RS-371 ORIGINAL SB NO. Subsection B of this Section is provided in a manner that limits disruptions in care, including the need for multiple biopsies or biospecimen samples. (2) Coverage required under Subsection B of this Section shall apply to the covered biomarker test itself and shall not be conditioned on laboratory classifications or credentialing standards …
Sponsors
- Talbot, Kirk (R, 10) · primary sponsor
- Chassion, Tehmi (D, 44)
Latest actions
- : Effective date 5/29/2026.
- : Signed by the Governor. Becomes Act No. 469.
- : Signed by the Speaker of the House.
- : Sent to the Governor by the Secretary of the Senate.
- : Enrolled. Signed by the President of the Senate.
- : Amendments proposed by the House read and concurred in by a vote of 34 yeas and 0 nays.
- : Received from the House with amendments.
- : Read third time by title, roll called on final passage, yeas 97, nays 0. Finally passed, ordered to the Senate.
- : Scheduled for floor debate on 05/12/2026.
- : Read by title, amended, passed to 3rd reading.
Votes
- Senate Vote on SB 169, CONCUR (#975) (May 19, 2026): 34 yea, 0 nay, passed
- House Vote on SB 169, FINAL PASSAGE (#1175) (May 12, 2026): 97 yea, 0 nay, passed
- Senate Vote on SB 169, FINAL PASSAGE (#318) (April 14, 2026): 35 yea, 0 nay, passed
Common questions
- What is SB169?
- SB169 is a bill in the Louisiana Legislature (2026 Regular Session): GENETICS: Provides relative to biomarker testing. (gov sig) (EN NO IMPACT See Note).
- What does SB169 do?
- In its own words: An act To amend and reenact R.S. 22:1028.5(D) and to enact R.S. 22:1028.5(B)(4) and (F), relative to biomarker testing; to clarify what constitutes clinical utility; to prevent coverage from being nullified through lab classification; to provide for construction of laws; to provide for an effective date; and to provide for related matters.
- What is the status of SB169?
- Signed into law as of May 29, 2026. Latest action: Effective date 5/29/2026. (May 29, 2026).
- Who sponsored SB169?
- Talbot, Kirk (R, 10), with 1 co-sponsor.
- Where is the official record for SB169?
- On the Louisiana Legislature website: https://legis.la.gov/legis/BillInfo.aspx?s=26RS&b=SB169
Source: official Louisiana record. Tracked by Delilah, AI for legislation across all 50 states and Congress.